Skip to content
value.today

Cambium Biomaterials, Inc.

Total raised
$120 M
3 rounds on record
Latest round
$94 M
Nov 2025
First round on record
Sep 2021
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cambium Biomaterials, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$94 MNo. 3$50 to $250 million

Cambium Biomaterials, Inc.: Raise no. 3, Nov 2025

Investors in this round

33 investors had bought by the notice of Dec 4, 2025: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$94 M of $101 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Griffin · Executive Officer
  • Nic Madren · Executive Officer
  • Simon Waddington · Executive Officer, Director
  • Stephan Herrera · Executive Officer
  • Tim Gardner · Executive Officer
  • Brett Schneider · Director
  • Christopher Pederson · Director
  • Francisco Gimenez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Simon Waddington, Chief Executive Officer. Newest notice filed Dec 4, 2025. Read the notice at the SEC.

equitySEC
Nov 2023$17 MNo. 2$10 to $50 million

Cambium Biomaterials, Inc.: Raise no. 2, Nov 2023

Investors in this round

16 investors had bought by the notice of Nov 14, 2023: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $20 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eliot Pence · Executive Officer
  • Simon Waddington · Executive Officer, Director
  • Stephan Herrera · Executive Officer
  • Francisco Gimenez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Simon Waddington, Chief Executive Officer. Newest notice filed Nov 14, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$8 MNo. 1$2 to $10 million

Cambium Biomaterials, Inc.: Raise no. 1, Sep 2021

Investors in this round

3 investors had bought by the notice of Sep 17, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $28 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Guenthner · Executive Officer
  • Simon Waddington · Executive Officer, Director
  • Stephan Herrera · Executive Officer, Director
  • Francisco Gimenez · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “TOTAL OFFERING AMOUNT AND TOTAL AMOUNT SOLD INCLUDES CONVERSION OF PREVIOUSLY ISSUED CONVERTIBLE SECURITIES.”

Signed by Simon Waddington, Chief Executive Officer. Newest notice filed Sep 17, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cambium Biomaterials, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Dec 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cambium Biomaterials, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cambium Biomaterials, Inc.
NameRoleNamed in
James GriffinExecutive officerDec 2025
Nic MadrenExecutive officerDec 2025
Simon WaddingtonExecutive officerDec 2025
Stephan HerreraExecutive officerDec 2025
Tim GardnerExecutive officerDec 2025
Eliot PenceExecutive officerNov 2023
Andrew GuenthnerExecutive officerSep 2021
Brett SchneiderDirectorDec 2025
Christopher PedersonDirectorDec 2025
Francisco GimenezDirectorDec 2025
Simon WaddingtonDirectorDec 2025
Stephan HerreraDirectorSep 2021